25 天前 - … (CML) contribute to treatment resistance and disease recurrence. Metabolism
regulates … after tyrosine kinase inhibitor (TKI) treatment. Deletion of HIF-2α suppresses disease …

27 天前 - … Introduction: Chronic myeloid leukemia (CML) is a hema… the introduction of different
tyrosine kinase inhibitors (TKIs), … As a result, coronary artery disease is anticipated to be the …

40 天前 - … In comparison to Ponatinib (tyrosine kinase inhibitor) which is … Chronic Myeloid
leukemia (CML) between 2018-2023. Cardiovascular events such as coronary artery disease (…

54 天前 - … Chronic myeloid leukemia (CML) is a clonal disorder … other tyrosine kinase inhibitors
(TKIs) targeting the ABL1 … is associated with serious cardiovascular adverse events [4], and …

59 天前 - … -generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with … for T315I-mutated chronic
myeloid leukemia (CML), CML … risk of toxicities, including cardiovascular risks. Ponatinib-…

63 天前 - … role, the first tyrosine kinase inhibitor (TKI), in treating chronic myelogenous leukemia
[2]. … As the molecular underpinnings of PPGL are being unraveled, a clear role of vascular …

66 天前 - … Chronic myeloid leukemia (CML) is a hematological … and the introduction of different
tyrosine kinase inhibitors (TKI), … As a result, coronary artery disease is anticipated to be the …

69 天前 - … Drugs showing emerging PAH association included other tyrosine kinase inhibitors
- … inhibitor bortezomib (probability: 0.8-0.9, p <0.0001). Chronic Myeloid Leukemia (CML) …

69 天前 - … tyrosine kinase inhibitor approved for first-line treatment of Philadelphia-positive
chronic myelogenous leukemia (… , skin rash, cardiac or autoimmune disease history, and age of …

109 天前 - … TKI ponatinib as a paradigm of cardiac toxicity. Ponatinib has … Chronic Myeloid
Leukemia (CML) due to T315I-ABL1 mutation, and has been associated with high risk of cardiac …